益生菌
健康福利
风险分析(工程)
生物
炎症体
免疫系统
生物技术
医学
重症监护医学
计算生物学
人类健康
不良结局途径
不利影响
生物信息学
动作(物理)
业务
免疫学
神经科学
过程(计算)
肠道菌群
炎症性肠病
钥匙(锁)
失调
临床试验
作者
Sumel Ashique,Biplab Debnath,Anas Islam,Mohammad Tariq,Tahreen Taj,Shubhrajit Mantry,Sathvik Belagodu Sridhar,Bharti Verma,Nitish Kumar,Krishnendu Adhikary,Dipali Saxena,Mudasir Maqbool,Md Sadique Hussain
标识
DOI:10.2174/0113816128411949250909113034
摘要
Para-probiotics, also referred to as non-viable microbial cells or cell components that confer health benefits, are emerging as promising agents in the prevention and management of inflammation-associated diseases. Unlike traditional probiotics, which require viability for efficacy, these inactivated forms offer significant advantages in terms of safety, stability, and applicability in vulnerable populations, including immunocompromised individuals. Recent studies have highlighted their capacity to modulate immune responses, enhance mucosal defense mechanisms, and reinforce intestinal barrier integrity through interactions involving microbial-associated molecular patterns (MAMPs) and host pattern recognition receptors. Such interactions influence signaling cascades like NF-κB, MAPKs, and inflammasome pathways, contributing to antiinflammatory and immunomodulatory effects. One of the key advantages is the reduced risk of adverse effects and concerns associated with live probiotic use. In addition, their robust physicochemical stability under industrial processing conditions supports their incorporation into a range of functional foods and nutraceuticals. Despite these advantages, their mechanisms of action remain incompletely understood and require further investigation. This review synthesizes current evidence on their anti-inflammatory properties, highlights preclinical and clinical studies, and discusses technological approaches for their production. Overall, these bioactives represent a safe, stable, and efficacious alternative to traditional probiotics in managing inflammatory disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI